Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy

Saigusa,Susumu; Tanaka,Koji; Ohi,Masaki; Toiyama,Yuji; Yasuda,Hiromi; Kitajima,Takahito; Okugawa,Yoshinaga; Inoue,Yasuhiro; Mohri,Yasuhiko; Kusunoki,Masato

doi:10.3892/mco.2014.431

Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy

Authors:
- Susumu Saigusa
- Koji Tanaka
- Masaki Ohi
- Yuji Toiyama
- Hiromi Yasuda
- Takahito Kitajima
- Yoshinaga Okugawa
- Yasuhiro Inoue
- Yasuhiko Mohri
- Masato Kusunoki
View Affiliations

Affiliations: Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan
Published online on: September 26, 2014 https://doi.org/10.3892/mco.2014.431
Pages: 151-156

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent epidemiological studies demonstrated that the incidence of esophageal squamous cell carcinoma (ESCC) is on the increase. Although neoadjuvant chemoradiotherapy (CRT) followed by surgery may improve long‑term survival and reduce local recurrence in patients with esophageal cancer, the overall cure rate of esophageal cancer is low. Fas/Fas ligand (FasL) signaling initiates the cell death pathway. The roles of FasL in tumor growth, progression and resistance to treatment have been demonstrated in several malignancies. The aim of this preliminary study was to evaluate Fas/FasL expression in ESCC with neoadjuvant CRT. A total of 20 patients who received neoadjuvant CRT (30‑40 Gy; 5‑fluorouracil plus cisplatin followed by surgery) were enrolled. We evaluated the expression of Fas, FasL and Ki67 (a proliferative marker) using immunohistochemistry and analyzed the correlations between their expression and clinical outcomes. Additionally, we investigated the association of Fas/FasL expression with peritumoral immune CD8‑positive and Foxp3‑positive cells. High FasL expression was significantly correlated with disease recurrence (P=0.0134). Patients with high FasL expression exhibited poorer recurrence‑free and overall survival (P=0.0102 and 0.0385, respectively). Patients with low Fas and high FasL exhibited significantly poorer recurrence‑free survival (P=0.0035). Although statistical significance was not reached, Fas expression appeared to be inversely correlated with Foxp3‑positive cells and FasL expression appeared to be inversely correlated with CD8‑positive cells. In conclusion, FasL expression was associated with tumor relapse and poor prognosis in patients with ESCC following CRT. Pharmacological control of Fas/FasL signaling may improve therapeutic efficacy and outcome in ESCC patients receiving preoperative CRT.

View Figures

View References

1	Stahl M, Stuschke M, Lehmann N, et al: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 23:2310–2317. 2005. View Article : Google Scholar : PubMed/NCBI
2	Lv J, Cao XF, Zhu B, Ji L, Tao L and Wang DD: Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol. 15:4962–4968. 2009. View Article : Google Scholar : PubMed/NCBI
3	Sjoquist KM, Burmeister BH, Smithers BM, et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12:681–692. 2011. View Article : Google Scholar : PubMed/NCBI
4	van Hagen P, Hulshof MC, van Lanschot JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012.
5	Igney FH and Krammer PH: Tumor counterattack: fact or fiction? Cancer Immunol Immunother. 54:1127–1136. 2005. View Article : Google Scholar : PubMed/NCBI
6	Shibakita M, Tachibana M, Dhar DK, et al: Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res. 5:2464–2469. 1999.PubMed/NCBI
7	Green DR and Ferguson TA: The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol. 2:917–924. 2001. View Article : Google Scholar : PubMed/NCBI
8	Abrahams VM, Kamsteeg M and Mor G: The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Mol Biotechnol. 25:19–30. 2003. View Article : Google Scholar : PubMed/NCBI
9	Scholz M and Cinatl J: Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev. 25:331–342. 2005. View Article : Google Scholar : PubMed/NCBI
10	Mitsiades N, Yu WH, Poulaki V, Tsokos M and Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61:577–581. 2001.PubMed/NCBI
11	Wang WS, Chen PM, Wang HS, Liang WY and Su Y: Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis. 27:1113–1120. 2006. View Article : Google Scholar : PubMed/NCBI
12	Almendro V, Ametller E, Garcia-Recio S, et al: The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS One. 4:e47282009. View Article : Google Scholar : PubMed/NCBI
13	Younes M, Schwartz MR, Ertan A, Finnie D and Younes A: Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer. 88:524–528. 2000. View Article : Google Scholar : PubMed/NCBI
14	Kase S, Osaki M, Adachi H, Kaibara N and Ito H: Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol. 20:291–297. 2002.PubMed/NCBI
15	Takikita M, Hu N, Shou JZ, et al: Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma. BMC Cancer. 9(310)2009. View Article : Google Scholar
16	Mandard AM, Dalibard F, Mandard JC, et al: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 73:2680–2686. 1994. View Article : Google Scholar
17	Wong SC, Lo SF, Lee KC, Yam JW, Chan JK and Wendy Hsiao WL: Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol. 196:145–153. 2002. View Article : Google Scholar : PubMed/NCBI
18	Saigusa S, Tanaka K, Ohi M, et al: Clinical significance of peritumoral mast cells in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Esophagus. 10:12–19. 2013. View Article : Google Scholar
19	Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P and Ohgaki H: Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 58:2057–2062. 1998.PubMed/NCBI
20	Rigberg DA, Centeno J, Kim FS, et al: Irradiation-induced up-regulation of Fas in esophageal squamous cell carcinoma is not accompanied by Fas ligand-mediated apoptosis. J Surg Oncol. 71:91–96. 1999. View Article : Google Scholar
21	Sun T, Miao X, Zhang X, Tan W, Xiong P and Lin D: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 96:1030–1036. 2004. View Article : Google Scholar : PubMed/NCBI
22	O'Brien DI, Nally K, Kelly RG, O'Connor TM, Shanahan F and O'Connell J: Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets. 9:1031–1044. 2005.
23	Villa-Morales M and Fernandez-Piqueras J: Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:85–101. 2012. View Article : Google Scholar : PubMed/NCBI